#Gilead Sciences

Results from randomized clinical trials of the antiviral drug continue to show mixed results.

The assurance arrives as the pharma giant cuts off most emergency access to remdesivir, a potential COVID-19 treatment.

Gilead Sciences’ direct-acting antiviral regimen was previously approved for adults.

Gilead Sciences is giving its antiviral remdesivir to nearly 1,000 people as part of two clinical trials.

Over 60 drugmakers raised prices an average of 5.8% on hundreds of drugs.

Three fatty liver disease candidates miss the mark for effectiveness or safety.

In a Phase II study, the drug was safe and well tolerated, and a small number of people achieved benchmarks of success against the virus.

A U.S. appeals court upheld a judge’s previous decision to throw out a record-setting 2016 verdict in Merck’s favor.

Drugs that have a favorable effect on biomarkers may still play a role in combination therapy, however.

A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.

Swiss researchers analyzed shifts in kidney function among those switching from the old form of the HIV medication to the new one.

Researchers compared outcomes among those with and without hep C before and after Sovaldi was approved in late 2013.

Selonsertib did not improve liver fibrosis more than a placebo.

Curing the virus was associated with a lower risk of liver cancer recurrence.

These drugs are approved to treat all six major genotypes of hepatitis C.